OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LNTH$94.5059

Lantheus Holdings Inc

Medical Equipment, Supplies & DistributionVerified

Lantheus Holdings Inc has a market capitalization of $6.14 billion and a price-to-earnings ratio of 26.29, which is above the industry median for medical equipment and supplies firms. The company's liquidity position is characterized by $359.12 million in cash and equivalents, but its long-term debt of $569.42 million results in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.52 suggests a moderate leverage profile, and the current ratio of 2.7 indicates a strong short-term liquidity position. In terms of profitability, Lantheus reports a return on equity (ROE) of 21.43% and a return on assets (ROA) of 10.49%, both of which are strong relative to the industry median. The company's operating margin is 19.97% (calculated from operating income of $310.83 million on revenue of $1.54 billion), and its net profit margin is 15.15% (calculated from net income of $233.56 million). These metrics suggest that Lantheus is effectively managing its costs and generating solid returns on its capital base. Geographically, Lantheus' revenue is primarily concentrated in the United States, with a significant portion derived from the diagnostic imaging market. The company's exposure to this market is a key driver of its revenue and profitability. There is no detailed breakdown of revenue by geographic region in the provided data, but the company's operations are largely domestic. Looking ahead, Lantheus is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's capital expenditure of -$36.09 million indicates a reduction in investment in physical assets, which may reflect a focus on optimizing existing operations rather than expanding capacity. The company's free cash flow of $267.57 million provides flexibility for dividends, share repurchases, or further investment in growth opportunities. The risk assessment for Lantheus highlights a medium liquidity risk due to the negative net cash position after accounting for long-term debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's risk profile is further supported by its strong operating cash flow of $390.14 million, which provides a buffer against potential financial stress. Recent events and disclosures indicate that Lantheus has not issued any new shares or engaged in significant capital-raising activities in the near term. The company's financial statements and disclosures do not suggest any immediate plans for equity dilution. The analyst estimates for Lantheus are mixed, with a mean price target of $92.77 and a median price target of $96.00, indicating a range of expectations among analysts.

30-day price · LNTH+21.33 (+26.1%)
Low$79.64High$103.89Close$103.00As of22 May, 00:00 UTC
Profile
CompanyLantheus Holdings Inc
TickerLNTH.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Lantheus Holdings Inc is a medical equipment and supplies company that develops, produces, and commercializes diagnostic imaging agents and related products for the healthcare industry.

Classification. Lantheus is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.

Lantheus Holdings Inc has a market capitalization of $6.14 billion and a price-to-earnings ratio of 26.29, which is above the industry median for medical equipment and supplies firms. The company's liquidity position is characterized by $359.12 million in cash and equivalents, but its long-term debt of $569.42 million results in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.52 suggests a moderate leverage profile, and the current ratio of 2.7 indicates a strong short-term liquidity position. In terms of profitability, Lantheus reports a return on equity (ROE) of 21.43% and a return on assets (ROA) of 10.49%, both of which are strong relative to the industry median. The company's operating margin is 19.97% (calculated from operating income of $310.83 million on revenue of $1.54 billion), and its net profit margin is 15.15% (calculated from net income of $233.56 million). These metrics suggest that Lantheus is effectively managing its costs and generating solid returns on its capital base. Geographically, Lantheus' revenue is primarily concentrated in the United States, with a significant portion derived from the diagnostic imaging market. The company's exposure to this market is a key driver of its revenue and profitability. There is no detailed breakdown of revenue by geographic region in the provided data, but the company's operations are largely domestic. Looking ahead, Lantheus is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's capital expenditure of -$36.09 million indicates a reduction in investment in physical assets, which may reflect a focus on optimizing existing operations rather than expanding capacity. The company's free cash flow of $267.57 million provides flexibility for dividends, share repurchases, or further investment in growth opportunities. The risk assessment for Lantheus highlights a medium liquidity risk due to the negative net cash position after accounting for long-term debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's risk profile is further supported by its strong operating cash flow of $390.14 million, which provides a buffer against potential financial stress. Recent events and disclosures indicate that Lantheus has not issued any new shares or engaged in significant capital-raising activities in the near term. The company's financial statements and disclosures do not suggest any immediate plans for equity dilution. The analyst estimates for Lantheus are mixed, with a mean price target of $92.77 and a median price target of $96.00, indicating a range of expectations among analysts.
Key takeaways
  • Lantheus Holdings Inc has a strong liquidity position with a current ratio of 2.7, but its net cash position is negative after accounting for long-term debt.
  • The company's profitability metrics, including a 21.43% ROE and 10.49% ROA, are robust and suggest effective capital utilization.
  • Lantheus' revenue is primarily concentrated in the United States, with a focus on the diagnostic imaging market.
  • The company is expected to maintain a stable growth trajectory, with a focus on optimizing existing operations rather than expanding capacity.
  • The risk assessment indicates a medium liquidity risk and a low dilution risk, with strong operating cash flow providing a financial buffer.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$1.54B
Gross profit$942.0M
Operating income$310.8M
Net income$233.6M
R&D
SG&A
D&A
SBC
Operating cash flow$390.1M
CapEx-$36.1M
Free cash flow$267.6M
Total assets$2.23B
Total liabilities$1.14B
Total equity$1.09B
Cash & equivalents$359.1M
Long-term debt$569.4M
Valuation
Market price$94.50
Market cap$6.14B
Enterprise value$6.35B
P/E26.3
Reported non-GAAP P/E
EV/Revenue4.1
EV/Op income20.4
EV/OCF16.3
P/B5.6
P/Tangible book5.6
Tangible book$1.09B
Net cash-$210.3M
Current ratio2.7
Debt/Equity0.5
ROA10.5%
ROE21.4%
Cash conversion1.7%
CapEx/Revenue-2.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricLNTHActivity
Op margin20.2%3.9% medp25 -31.3% · p75 14.4%top quartile
Net margin15.2%2.4% medp25 -30.5% · p75 11.1%top quartile
Gross margin61.1%46.7% medp25 28.2% · p75 63.1%above median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.3%-4.8% medp25 -11.6% · p75 -2.4%top quartile
Debt / equity52.0%17.9% medp25 2.7% · p75 52.2%above median
Observations
IR observations
Mean price target92.77 USD
Median price target96.00 USD
High price target114.00 USD
Low price target70.00 USD
Mean recommendation1.92 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count8.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate5.17 USD
Last actual EPS6.08 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 05:40 UTC#61923d0a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 10:55 UTCJob: 48267438